Genentech recently announced the results of a Phase II study entitled BIRCH for the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1). Primary endpoints for BIRCH study investigating the therapeutic benefit of atezolizumab in patients ... Read more